Target intelligence / Profile preview

Hexokinase–VDAC complex

Molecular classification
Protein complex, Enzyme complex, Channel-associated complex, Outer mitochondrial membrane protein complex
01

Overview

The hexokinase–VDAC complex refers to the physical and functional association between hexokinase isoforms (especially hexokinase-I and hexokinase-II) and the voltage-dependent anion channel (VDAC) of the outer mitochondrial membrane. This interaction facilitates direct access of hexokinase to mitochondrial ATP, thereby supporting efficient glycolysis. Binding of hexokinase also confers protection against apoptosis by preventing the association of pro-apoptotic proteins (such as Bax) with the mitochondria and by modulating the mitochondrial permeability transition pore. The complex is particularly abundant in cancer cells due to upregulated hexokinase-II, promoting the metabolic phenotype known as the Warburg effect. Disruption of this protein–protein interaction sensitizes cells to cell death, making the hexokinase–VDAC complex an attractive, though challenging, therapeutic target for cancer and possibly other diseases involving mitochondrial dysfunction.

Other names
Mitochondrially-bound hexokinase–VDAC complexHexokinase–voltage-dependent anion channel complexHK–VDAC complexMitochondrial hexokinase–VDAC complex
02

Mechanism of action

Inhibitors disrupt binding of hexokinase to VDAC, promoting apoptosis and sensitizing cells (notably cancer cells) to cell death

03

Biological functions

Regulation of apoptosisCellular metabolism (glycolysis and ATP production)Modulation of ion/metabolite exchange across the mitochondrial outer membraneProtection from cell death
04

Disease associations

CancerNeurodegenerative diseaseInflammationCardiovascular disease
05

Safety considerations

Interfering with this complex can trigger cell death in healthy tissue and impair cellular energy homeostasis, raising concerns for off-target toxicity, especially in metabolically active organs
06

Interacting drugs

No direct, approved drugs specifically target the complex, but molecules such as 3-bromopyruvate and clotrimazole have been shown to disrupt the HK–VDAC interaction in research settings; some chemotherapeutic agents may also indirectly affect the interaction via signaling pathways
07

Biomarkers

Overexpression of hexokinase-II on mitochondria (as in many cancers) may serve as a biomarker for metabolic reprogramming (Warburg effect) and potentially for response to drugs targeting the complex

Beyond the preview

Go deeper on Hexokinase–VDAC complex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexokinase–VDAC complex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call